Natixis Advisors L.P. Has $1.90 Million Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Natixis Advisors L.P. decreased its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 45.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,425 shares of the specialty pharmaceutical company's stock after selling 12,690 shares during the quarter. Natixis Advisors L.P.'s holdings in Jazz Pharmaceuticals were worth $1,897,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in JAZZ. Commonwealth Equity Services LLC lifted its stake in Jazz Pharmaceuticals by 10.6% in the 3rd quarter. Commonwealth Equity Services LLC now owns 10,073 shares of the specialty pharmaceutical company's stock valued at $1,304,000 after buying an additional 962 shares in the last quarter. Advisor Partners II LLC acquired a new position in shares of Jazz Pharmaceuticals in the 3rd quarter worth approximately $231,000. First Trust Direct Indexing L.P. purchased a new position in shares of Jazz Pharmaceuticals in the third quarter valued at approximately $208,000. CIBC Asset Management Inc boosted its position in Jazz Pharmaceuticals by 5.6% in the 3rd quarter. CIBC Asset Management Inc now owns 2,264 shares of the specialty pharmaceutical company's stock valued at $293,000 after buying an additional 121 shares during the period. Finally, Fifth Third Bancorp increased its holdings in Jazz Pharmaceuticals by 2.2% during the 3rd quarter. Fifth Third Bancorp now owns 5,339 shares of the specialty pharmaceutical company's stock worth $691,000 after purchasing an additional 114 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Down 2.0 %

Shares of NASDAQ JAZZ traded down $2.27 on Wednesday, hitting $109.74. The company had a trading volume of 812,901 shares, compared to its average volume of 621,217. The firm has a market capitalization of $6.92 billion, a P/E ratio of 22.63, a PEG ratio of 1.66 and a beta of 0.63. The company has a quick ratio of 1.90, a current ratio of 2.27 and a debt-to-equity ratio of 1.38. Jazz Pharmaceuticals plc has a 12-month low of $103.01 and a 12-month high of $146.70. The business has a 50 day moving average of $114.51 and a two-hundred day moving average of $119.95.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share for the quarter, missing analysts' consensus estimates of $4.44 by ($0.04). The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1.01 billion. Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. As a group, equities research analysts forecast that Jazz Pharmaceuticals plc will post 15.38 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on JAZZ. Cantor Fitzgerald restated an "overweight" rating and set a $180.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, April 10th. HC Wainwright reissued a "buy" rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Friday, May 3rd. Barclays dropped their target price on shares of Jazz Pharmaceuticals from $230.00 to $200.00 and set an "overweight" rating for the company in a report on Friday, May 3rd. Truist Financial reissued a "buy" rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 20th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $222.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, May 2nd. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $192.75.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,936 shares of the stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total transaction of $231,623.04. Following the sale, the chief accounting officer now directly owns 8,364 shares of the company's stock, valued at $1,000,668.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Philip L. Johnson bought 12,000 shares of the business's stock in a transaction dated Friday, March 1st. The shares were bought at an average cost of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the transaction, the chief financial officer now directly owns 27,932 shares of the company's stock, valued at $3,342,063.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Patricia Carr sold 1,936 shares of the stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the transaction, the chief accounting officer now owns 8,364 shares of the company's stock, valued at approximately $1,000,668.96. The disclosure for this sale can be found here. 4.40% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.